SOLVING THE PROBLEM OF MULTIDRUG RESISTANCE: ABC TRANSPORTERS IN CLINICAL ONCOLOGY

ABC Proteins: from Bacteria to Man

Volumn , Issue , 2003, Pages 359-391

  Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85163513522     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012352551-2/50019-6     Document Type: Chapter

References (227)

1. A. Abolhoda, A.E. Wilson, H. Ross, P.V. Danenberg, M. Burt and K.W. Scotto (1999) Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5 3352-3356.
2. R. Advani, H.I. Saba, M.S. Tallman, J.M. Rowe, P.H. Wiernik, J. Ramek, et al. (1999) Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93 787-795.
3. R. Advani, G.A. Fisher, B.L. Lum, J. Hausdorff, J. Halsey, M. Litchman and B.I. Sikic (2001) A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin. Cancer Res. 7 1221-1229.
4. J.D. Allen, R.F. Brinkhuis, L. van Deemter, J. Wijnholds and A.H. Schinkel (2000) Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 60 5761-5766.
5. R. Allikmets, L.M. Schriml, A. Hutchinson, V. Romano-Spica and M. Dean (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58 5337-5339.
6. M. Arnal, N. Franco, P. Fargeot, J.M. Riedinger, P. Brunet-Lecomte and S. Lizard-Nacol (2000) Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res. Treat. 61 13-20.
7. H.J. Arts, D. Katsaros, E.G. de Vries, M. Massobrio, E. Genta, S. Danese, et al. (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin. Cancer Res. 5 2798-2805.
8. M.M. Baekelandt, R. Holm, J.M. Nesland, C.G. Trope and G.B. Kristensen (2000) P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 20 1061-1067.
9. M. Baekelandt, G. Lehne, C.G. Trope, I. Szanto, P. Pfeiffer, B. Gustavssson and G.B. Kristensen (2001) Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J. Clin. Oncol. 19 2983-2993.
10. M. Bakker, W.T. van der Graaf, D.A. Piers, E.J. Franssen, H.J. Groen, E.F. Smit, W. Kool, H. Hollema, E.A. Muller and E.G. De Vries (1999) 99mTc-Sestamibi scanning with SDZPSC 833 as a functional detection method for resistance modulation in patients with solid tumours. Anticancer Res. 19 2349-2353.
11. E. Bakos, R. Evers, G. Szakacs, G.L. Tusnadv, E. Welker, K. Szabo, et al. (1998) Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem. 273 32167-32175.
12. N. Baldini, K. Scotlandi, G. Barbanti-Brodano, M.C. Manara, D. Maurici, G. Bacci, et al. (1995) Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 333 1380-1385.
13. S. Bates, M. Kang, B. Meadows, S. Bakke, P. Choyke, M. Merino, et al. (2001) A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (Valspodar). Cancer 92 1577-1590.
14. W.T. Beck, T.I. Mueller and L.R. Tanzer (1979) Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 39 2070-2076.
15. W.T. Beck, T.M. Grogan, C.L. Willman and D.M. Parham (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 56 3010-3020.
16. L. Beketic-Oreskovic, G.E. Duran, G. Chen, C. Dumontet and B.I. Sikic (1995) Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J. Natl Cancer Inst. 87 1593-1602.
17. J.L. Biedler and R.H.F. Peterson (1981) Molecular Actions and Targets for Cancer. A. Sartorelli, J. Lazo, J. Bertino (Eds) Chemotherapeutic Agents New York: Academic Press 453-482.
18. B. Bodey, B.B. Bodey, A.M. Groger, J.N. Luck, S.E. Siegel, C.R. Taylor and H.E. Kaiser (1997) Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance. Anticancer Res. 17 1311-1318.
19. M. Bohme, M. Buchler, M. Muller and D. Kepplet (1993) Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett. 333 193-196.
20. M. Bohme, M. Muller, I. Leier, G. Jedlitschky and D. Keppler (1994) Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 107 255-265.
21. D.J. Boote, I.F. Dennis, P.R. Twentyman, R.J. Osborne, C. Laburte, S. Hensel, J.F. Smyth, M.H. Brampton and N.M. Fleehen (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14 610-618.
22. P. Borst and A.H. Schinkel (1996) What have we learnt thus far from mice with disrupted P-genes? Eur. J. Cancer 32A 985-990.
23. P. Borst, N. Zelcer and A. van Helvoort (2000) ABC transporters in lipid transport. Biochim. Biophys. Acta 1486 128-144.
24. P. Borst, R. Evers, M. Kool and J. Wijnholds (2000) A family of drug transporters: the multidrug resistance-associated proteins. J. Natl Cancer Inst. 92 1295-1302.
25. D.M. Bradshaw and R.J. Arceci (1998) Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. 16 3674-3690.
26. M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo and S.E. Bates (1999) Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59 5938-5946.
27. C. Broccardo, M. Luciani and G. Chimini (1999) The ABCA subclass of mammalian transporters. Biochim. Biophys. Acta 1461 395-404.
28. H.J. Broxterman, P. Sonneveld, R. Pieters, I. Lankelma, C.A. Eekman, A.H. Loonen, et al. (1999) Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia 13 258-265.
29. H.J. Bronterman, P. Sonneveld, W.J. van Putten, J. Lankema, C.A. Eekman, G.J. Ossenkoppele, H.M. Pinedo, B. Lowerberg and G.J. Schuurhuis (2000) P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia 14 1018-1024.
30. M. Buchler, J. Konig, M. Brom, J. Kartenbeck, H. Spring, T. Horie and D. Keppler (1996) cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271 15091-15098.
31. J.H. Burchenal, E. Robinson, S.E. Johnston and M.N. Kushida (1950) The induction of resistance to 4-amino-N10-methyl-pteroylglutamic acid in a strain of transmitted mouse leukemia. Science 111 116.
32. L. Campos, D. Guyotat, E. Archimbaud, P. Calmard-Oriol, J. Isuruo, J. Troncy, D. Treille and D. Friere (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79 473-476.
33. H.S.L. Chan, P.S. Thorney, G. Haddad and V. Ling (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 50 2818-2822.
34. H.S. Chan, T.M. Grogan, G. Haddad, G. DeBoer and V. Ling (1997) P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J. Natl Cancer Inst. 89 1706-1715.
35. T.R. Chauncey, C. Rankin, J.E. Anderson, J. Chen, K.I. Kopecky, J.E. Godwin, et al. (2000) A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617. Leuk. Res. 24 567-574.
36. C.C. Chen, B. Meadows, J. Regis, G. Kalafsky, T. Lojo, J.A. Carrasquillo and S.E. Bates (1997) Detection of in vivo p-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin. Cancer Res. 4 545-552.
37. Y.-N. Chen, L.A. Mickley, A.M. Schwartz, E.M. Acton, J. Hwang and A.T. Fojo (1990) Characterization of Adriamycin-resistant human breast cancer cells which display over-expression of a novel resistance-related membrane protein. J. Biol. Chem. 265 10073-10080.
38. Z. Chen, K. Lee and G.D. Kruh (2001) Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4: resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. 276 33747-33754.
39. Z.S. Chen, T. Eurukawa, T. Sumizawa, K. Ono, K. Ueda, K. Seto and S.I. Akiyama (1999) ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol. Pharmacol. 55 921-928.
40. S. Chevillard, P. Pouillart, C. Beldjord, B. Assetain, P. Beuzeboc, H. Magdelenal and P. Vielh (1996) Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neo-adjuvant chemotherapy. Cancer 77 292-300.
41. L. Chico, M.H. Kang, R. Bergan, J. Abraham, S. Bakke, B. Meadows, et al. (2001) Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J. Clin. Oncol. 19 832-842.
42. S. Childs, R.L. Yeh, E. Georges and V. Ling (1995) Identification of a sister gene to P-glycoprotein. Cancer Res. 55 2029-2034.
43. S. Childs, R.L. Yeh, D. Hui and V. Ling (1998) Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res. 58 4160-4167.
44. H.C. Chung, S.Y. Rha, J.H. Kim, J.K. Roh, J.S. Min, K.S. Lee, B.S. Kim and K.B. Lee (1997) P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res. Treat. 42 65-72.
45. A. Ciarmiello, S. Del Vecchio, P. Silvestro, M.I. Potena, M.V. Carriero, R. Thomas, G. Botti, G. D'Aiuto and M. Salvatore (1998) Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J. Clin. Oncol. 16 1677-1683.
46. S.P.C. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M. Duncan and R.G. Deeley (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 1650-1654.
47. S.P.C. Cole, K.F. Sparks, K. Fraser, D.W. Loe, C.E. Grant and G.M. Wilson (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54 5902-5910.
48. H.M. Coley, M.W. Verrill, S.E. Gregson, D.E. Odell, C. Fisher and I.R. Judson (2000) Incidence of P-glycoprotein over-expression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur. J. Cancer 36 881-888.
49. C. Cordon-Cardo, J.P. O'Brien, D. Casals, L. Ritlman-Grauer, J.L. Biedler, M.R. Melamed and J.R. Bertino (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl Acad. Sci. USA 86 695-698.
50. C. Cordon-Cardo, J.P. O'Brien, J. Boccia, D. Casals, J.R. Bertino and M.R. Melamed (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. cytochem. 38 1277-1287.
51. Y. Cui, J. Konig, J.K. Buchbolz, H. Spring, I. Leier and D. Keppler (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55 929-937.
52. K. Dano (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta 323 466-483.
53. A.H. Dantzig, R.L. Shepard, K.L. Law, L. Tabas, S. Pratt, J.S. Gillespie, S.N. Binkley, M.T. Kuhfeld, J.J. Starling and S.A. Wrighton (1999) Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290 854-862.
54. M. de Bruin, K. Miyake, T. Litman, R. Robey and S.E. Bates (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 146 117-126.
55. M. Dean, Y. Hamon and G. Chimini (2001) The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42 1007-1017.
56. S. Del Vecchio, A. Ciarmiello, L. Pace, M.L. Potena, M.V. Carriero, C. Mainolfi, R. Thomas, G. D'Aiuto, T. Tsuruo and M. Salvatore (1997) Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J. Nucl. Med. 38 1348-1351.
57. M.L. den Boer, R. Pieters, K.M. Kazemier, M.M. Rottier, C.M. Zwaan, G.J. Kaspers, et al. (1998) Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91 2092-2098.
58. D.W. Dexter, R.K. Reddy, K.G. Geles, S. Bansal, M.A. Myint, A. Rogakto, J.C. Leighton and I.J. Goldstein (1998) Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res. 4 1533-1542.
59. R. Dorr, C. Karanes, C. Spier, T. Grogan, J. Greer, J. Moore, et al. (2001) Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J. Clin. Oncol. 19 1589-1599.
60. L.A. Doyle, W. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, A.K. Rishi and D.D. Ross (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95 15665-15670.
61. J.H. Edmonson, L.M. Ryan, R.H. Blum, J.S. Brooks, M. Shiraki, S. Frytak and D.R. Parkinson (1993) Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11 1269-1275.
62. R. Evers, G.J. Zaman, L. van Deemter, H. Jansen, J. Calafat, L.C. Oomen, R.P. Oude Elferink, P. Borst and A.H. Schinkel (1996) Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 97 1211-1218.
63. I.E. Faneyte, P.M. Kristet and M.J. van de Vijver (2001) Determining MDR1/P-glycoprotein expression in breast cancer. Int. J. Cancer 93 114-122.
64. D.R. Ferry, H. Traunecker and D.J. Kerr (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer 32A 1070-1081.
65. M. Filipits, R.W. Suchomel, G. Dekan, K. Haider, G. Valdimarsson, D. Depisch and R. Pirker (1996) MRP and MDR1 gene expression in primary breast carcinomas. Clin. Cancer Res. 2 1231-1237.
66. M. Filipits, G. Pohl, T. Stranzl, R.W. Suchomel, R.J. Scheper, U. Jager, K. Geissler, K. Lechner and R. Pirker (1998) Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91 1508-1513.
67. G.A. Fisher and B.I. Sikic (1995) Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. North Am. 9 363-382.
68. G.A. Fisher, B.L. Lum, J. Hausdorff and B.I. Sikic (1996) Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer 32A 1082-1088.
69. A.T. Fojo, K. Ueda, D.J. Slamon, D.G. Poplack, M.M. Gottesman and I. Pastan (1987) Expression of a multidrug resistance gene in human tumors and tisues. Proc. Natl Acad. Sci. USA 84 265-269.
70. P.M. Fracasso, P. Westerveldt, C.L. Fears, D.M. Rosen, E.G. Zuhowski, L.A. Cazenave, M. Litchman, M.J. Egorin, P. Westervelt and C.A. Fears (2000) Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J. Clin. Oncol. 18 1124-1134.
71. P.M. Fracasso, M.F. Brady, D.H. Moore, J.L. Walker, P.G. Rose, L. Letvak, T.M. Grogan and W.P. McGuire (2001) Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 19 2975-2982.
72. H. Fujii, K. Nakamura, A. Kubo, K. Enomoto, T. Ikeba, J. Kubola, S.W. Matsuzaki and M. Kitajima (1998) 99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer. Anticancer Res. 18 4601-4605.
73. B.W. Futscher, N.E. Foley, M.C. Gleason-Guzman, P.S. Meltzer, D.M. Sullivan and W.S. Dalton (1999) Verapamil suppresses the emergence of P-glycoprotein-mediated multidrug resistance. Int. J. Cancer 66 520-525.
74. S. Galimberti, A. Marchetti, F. Buttitta, V. Carnelli, S. Pellegrini, G. Bevilacqua and M. Petrini (1998) Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res. 18 2973-2976.
75. J.H. Gerlach, J.A. Endicott, P.F. Juranka, G. Henderson, F. Sarangi, K.L. Deuchars and V. Ling (1956) Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324 485-489.
76. T. Gerloft, B. Stieger, B. Hagenbuch, J. Madon, L. Landmann, J. Roth, A.F. Hotmann and P.I. Meier (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273 10046-10050.
77. U.A. Germann, P.J. Ford, D. Shlyakhter, V.S. Mason and M.W. Harding (1997) Chemosensitization and drug accumulation effects of VX-710, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drug 8 141-155.
78. G. Giaccone, S.C. Linn, J. Welink, G. Catimel, H. Stieltjes, M.J. van der Vijgh, C. Eeltink, J.B. Vermorken and H.M. Pinedo (1997) A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. 3 2005-2015.
79. P. Giannakakou, R. Gussio, F. Nogales, K.H. Downing, D. Zaharevitz, B. Bollbuck, G. Poy, D. Sackett, K.C. Nicolaou, G. Poy, D. Sackett, K.C. Nicolaou and T. Fojo (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl Acad. Sci. USA 97 2904-2909.
80. B.A. Goff, P.J. Paley, B.E. Greet and A.M. Gown (2001) Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol. Oncol. 81 18-24.
81. L.J. Goldstein, H. Galski, A. Fojo, M. Willingham, S.L. Lai, A. Gazder, et al. (1989) Expression of a multidrug resistance gene in human cancers. J. Natl Cancer Inst. 81 116-124.
82. M.M. Gottesman and I. Pastan (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62 385-427.
83. P. Cros, J. Croop and D. Housman (1986) Mammalian multidrug resistance genes: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47 371-380.
84. K. Han, J. Kahng, M. Kim, J. Lim, Y. Kim, B. Cho, et al. (2000) Expression of functional markers in acute nonlymphoblastic leukemia. Acta. Haematol. 104 174-180.
85. A.K. Haque, P. Adegboyega, A. Al-Salameh, D.P. Vrazel and J. Zwischenberger (1999) p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review. Mod. Pathol. 12 1158-1166.
86. S. Hegewisch-Becker, E. Staib, T. Loning, U. Pichlmeier, N. Kroger, A. Reymann and D.K. Hossfeld (1998) No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer. Ann. Oncol. 9 85-93.
87. N.H. Hendrikse, E.J.F. Franssen, W.T.A. van der Graaf, C. Meijer, D.A. Piers, W. Vaalburg and E.G.E. de Vries (1998) 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br. J. Cancer 77 353-358.
88. C.E. Herzog, J.B. Trepel, L.A. Mickley, S.E. Bates and A.T. Fojo (1992) Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. J. Natl Cancer Inst. 84 711-716.
89. D.R. Hipfner, M. Gao, G. Scheffer, R.J. Scheper, R.G. Deeley and S.P.C. Cole (1998) Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP). Br. J. Cancer 78 1134-1140.
90. D.R. Hipfner, R.G. Deeley and S.P.C. Cole (1999) Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461 359-376.
91. Y. Honjo, C.A. Hrycyna, Q.-W. Yan, W.Y. Medina-Perez, R.W. Robey, A. van de Laan, I. Litman, M. Dean and S.E. Bates (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61 6635-6639.
92. A.H. Honskoop, P.J. van Diest, J.S. de long, S.C. Linn, G. Giaccone, K. Hoekman, J. Wagstaff and H.M. Pinedo (1998) Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br. J. Cancer 77 621-626.
93. J.H. Hooijberg, H.J. Broxterman, M. Kool, Y.G. Assaraf, G.J. Peters, P. Noordhuis, R.J. Scheper, P. Borst, H.M. Pinedo and G. Jansen (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59 2532-2535.
94. M.A. Izquierdo, A.G. van der Zee, J.B. Vermorken, V.P. van den Valk^P., J.A. Belien, G. Giaccone, et al. (1995) Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl Cancer Inst. 87 1230-1237.
95. J.P. Jaffrezou, C. Dumontet, W.B. Derry, G. Duran, G. Chen, E. Tsuchiya, L. Wilson, M.A. Jordan and B.J. Sikic (1995) Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol. Res. 7 517-527.
96. G. Jedlitschky, I. Leier, U. Buchholz, M. Center and D. Keppler (1999) ATP-dependent transport of glutathion S-conjugates by multidrug resistance-associated protein. Cancer Res. 54 4833-4836.
97. G. Jedlitschky, I. Leier, L. Buchholz, K. Barnouin, G. Kurz and D. Keppler (1996) Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 56 988-994.
98. G. Jedlitschky, B. Burchell and D. Keppler (2000) The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 275 30069-30074.
99. F. Joncourt, K. Buser, H. Altermatt, M. Bacchi, A. Oberti and T. Cerny (1998) Multiple drug resistance parameter expression in ovarian cancer. Gynecol. Oncol. 70 176-182.
100. J.W. Jonker, J.W. Smit, R.F. Brinkhuis, M. Maliepaard, J.H. Beijnen, J.H. Schellens and A.H. Schinkel (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl Cancer Inst. 92 1651-1656.
101. A. Kanzaki, M. Toi, K. Nakayama, H. Bando, M. Mutoh, T. Uchida, M. Fukumoto and Y. Takebayashi (2001) Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J. Cancer Res. 92 452-458.
102. C.H. Kao, S.P. ChangLai, P.U. Chieng and T.C. Yen (1998) Technetium-99m methoxyisobytylisonitrile chest imaging of small cell lung carcinoma: relation to patient prognosis and chemotherapy response—a preliminary report. Cancer 83 64-68.
103. C.H. Kao, J.F. Hsieh, S.C. Tsai, Y.J. Ho and J.K. Jee (2000) Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. Clin. Cancer Res. 6 820-824.
104. C.H. Kao, S.C. Tsai, T.J. Liu, Y.J. Ho, J.J. Wang, S.T. Ho and S.P. ChangLai (2001) P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Res. 61 1412-1414.
105. C.H. Kao, S.C. Tsai, J.J. Wang, Y.J. Ho, S.T. Ho and S.P. Changlai (2001) Evaluation of chemotherapy response using technetium-99M-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report. Int. J. Cancer 95 228-231.
106. K.T. Kivisto, H.K. Kroemer and M. Eichelbaum (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interations. Br. J. Clin. Pharmacol. 40 523-530.
107. I. Klein, B. Sarkadi and A. Varadi (1999) An inventory of the human ABC proteins. Biochim. Biophys. Acta 1461 237-262.
108. T. Knutsen, V.K. Rao, T. Ried, L. Mickley, E. Schneider, K. Miyake, et al. (2000) Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantroneresistant cell lines. Genes Chrom. Cancer 27 110-116.
109. K. Koike, T. Kawabe, T. Tanaka, S. Toh, T. Uchiumi, M. Wada, S. Akiyama, M. Ono and M. Kuwano (1997) A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 57 5475-5479.
110. T. Komori, I. Narabayashi, R. Matsui, K. Sueyoshi, L. Artani and K. Utsunomiya (2000) Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer-preliminary report. Ann. Nucl. Med. 14 415-420.
111. J. Konig, D. Rost, Y. Cui and D. Keppler (1999) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29 1156-1163.
112. M. Kool, M. de Haas, G.L. Scheffer, R.J. Scheper, M.J. van Eijk, J.A. Juijn, F. Baas and P. Borst (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene in human cancer cell lines. Cancer Res. 57 3537-3547.
113. M. Kool, M. van der Linden, M. de Haas, G.L. Scheffer, J.M. de Vree, A.J. Smith, et al. (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl Acad. Sci. USA 96 6914-6919.
114. S.M. Kornblau, E. Estey, T. Madden, H.T. Tran, S. Zhao, U. Consoli, et al. (1997) Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J. Clin. Oncol. 15 1796-1802.
115. L. Kostakoglu, S. Ruacan, E.L. Ergun, I. Sayek, N. Elahi and C.F. Bekdik (1998) Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. J. Nucl. Med. 39 1021-1026.
116. G.A. Kullak-Ublick, B. Stieger, B. Hagenbuch and P.J. Meier (2000) Hepatic transport of bile salts. Semin. Liver Dis. 20 273-292.
117. J.F. Kuttesch, D.M. Parham, X. Luo, W.H. Meyer, L. Bowman, D.N. Shapiro, A.S. Pappo, W.M. Crist, W.T. Beck and P.J. Honghton (1996) P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J. Clin. Oncol. 14 886-900.
118. R. Lacave, L. Coulet, S. Ricci, E. Touboul, A. Flahault, J.G. Rateau, D. Cesari, J.P. Lefranc and J.F. Bernaudin (1986) Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas. Br. J. Cancer 77 694-702.
119. N.M. Laing, M.G. Belinsky, G.D. Kruh, D.W. Bell, J.T. Boyd, L. Barone, J.R. Testa and K.D. Tew (1998) Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res. 58 1332-1337.
120. E.J. Lee, S.L. George, M. Caligiuri, T.P. Szatrowski, B.L. Powell, S. Lemke, R.K. Dodge, R. Smith, M. Baer and C.A. Schiffer (1999) Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. J. Clin. Oncol. 17 2831-2839.
121. P.D. Lee, S.E. Noble-Topham, R.S. Bell and I.L. Andrulis (1996) Quantitative analysis of multidrug resistance gene expression in human osteosarcomas. Br. J. Cancer 74 1046-1050.
122. O. Legrand, G. Simonin, A. Beauchamp-Nicoud, R. Zittoun and J.P. Marie (1999) Simultaneous activity of MRP1 and P-glycoprotein is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94 1046-1056.
123. M. Lehnert, K. Mross, J. Schueller, B. Thuerlimann, N. Kroeger and H. Kupper (1998) Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br. J. Cancer 77 1155-1163.
124. C.P. Leith, K.J. Kopecky, I.M. Chen, L. Eijdems, M.L. Slovak, T.S. McConnell, et al. (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94 1086-1099.
125. E.M. Leslie, R.G. Deeley and S.P.C. Cole (2001) Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167 3-23.
126. E.A. Levine, T. Holzmayer, S. Bacus, E. Mechetner, R. Mera, C. Bolliger, I.B. Roninson and T.K. Das Gupta (1997) Evaluation of newer prognostic markers for adult soft tissue sarcomas. J. Clin. Oncol. 15 3249-3257.
127. S.C. Linn, H.M. Pinedo, P. der Valk, K. Hoekman, A.H. Honkoop, J.B. Vermorken and G. Giaccone (1997) Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int. J. Cancer 71 787-795.
128. A.F. List, C. Spier, J. Greer, S. Wolff, J. Hurter, R. Dorr, S. Salmon, B. Futscher, M. Baier and W. Dalton (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 11 1652-1660.
129. A.F. List, C.S. Spier, D.J. Roe, J.P. Greer, et al. (1996) Over-expression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87 2464-2469.
130. T. Litman, M. Brangi, L. Hudson, P. Fetsch, D.D. Koss, K. Miyake, J.J.H. Resau and S.E. Bates (2000) The multidrug resistant phenotype associated with overexpression of the new ABC half-transporter, MXR. J. Cell Sci. 113 2011-2021.
131. J.M. Riedinger, M. Arnal, C. Sancy, P. Brunet-Lecomte and P. Fargeol (1999) MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res. 19 3575-3581.
132. D.W. Loe, R.G. Deeley and S.P.C. Cole (1998) Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58 5130-5136.
133. J.M. Lopes, O.S. Bruland, B. Bjerkehagen, M.C. Silva, R. Holm, E.O. Pettersen, O.P. Solheim, M. Sobrinho-Simoes and J.M. Nesland (1997) Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferasepi and clinical drug resistance. Pathol. Res. Pract. 193 21-36.
134. A. Lorico, G. Rappa, R.A. Flavell and A.C. Sartorelli (1996) Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res. 56 5351-5355.
135. G.D. Luker, P.M. Facasso, J. Dobkin and D. Piwnica-Worms (1997) Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J. Nucl. Med. 38 369-372.
136. M.A. van Gastelen, L.A. de Jong, D. Pluim, R.C. van Waardenburg, M.C. Ruevekamp-Helmers, B.G. Floot and J.H. Schellens (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59 4559-4563.
137. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C.L.M. Pijnenborg, A.H. Schinkel, M.J. van de Vijver, R.J. Scheper and J.H.M. Schellens (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61 3458-3464.
138. M. Masuda, Y. Fizuka, M. Yamazaki, R. Nishigaki, Y. Kato, K. Ni'inuma, H. Suzuki and Y. Sugiyama (1997) Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 57 3506-3510.
139. E. Mechetner, A. Kyshtoobayeva, S. Zonis, H. Kim, R. Stroup, R. Garcia, R.J. Parker and J.P. Fruebauf (1998) Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer Res. 4 389-398.
140. M. Michieli, D. Damiani, A. Ermacora, P. Masolini, D. Raspadori, G. Visani, R.J. Scheper and M. Baccarani (1999) P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br. J. Haematol. 104 328-335.
141. L. Mickley, P. Jain, K. Miyake, L.M. Schriml, K. Rao, T. Fojo, S. Bates and M. Dean (2001) An ATP-binding cassette gene (ABCG3) closely related to the multidrug transporter ABCG2 (MXR/ABCP) has an unusual ATP-binding domain. Mamm. Genome 12 86-88.
142. T.P. Miller, E.M. Chase, R. Dorr, W.S. Dalton, K.S. Lam and S.E. Salmon (1998) A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drug. 9 135-140.
143. H. Minami, T. Ohtsu, H. Fujii, T. Igarashi, K. Itoh, N. Uchiyama-Kokubu, et al. (2001) Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. Jpn J. Cancer Res. 92 220-230.
144. P. Mistry, A.J. Stewart, W. Dangerfield, S. Okiji, C. Liddle, D. Bootle, J.A. Plumb, D. Templeton and P. Charlton (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 61 749-758.
145. K. Miyake, L. Mickley, T. Litman, Z. Zhan, R. Robey, B. Cristensen, et al. (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59 8-13.
146. E. Narasaki, I. Matsuo, N. Ikuno, M. Fukuda, H. Soda and M. Oka (1996) Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Anticancer Res. 16 2079-2082.
147. M.I. Newman, I.C. Rodarte, K.D. Benbatoul, S.J. Romano, C. Zhang, S. Krane, et al. (2000) Discovery and characterization of OC144-093, a novel inhibitor of P-glyco-protein-mediated multidrug resistance. Cancer Res. 60 2964-2972.
148. Y. Nishiyami, Y. Yamamoto, K. Satoh, M. Ohkawa, K. Kameyama, E. Hayashi, J. Fujita and M. Tanabe (2000) Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin. Nucl. Med. 25 364-369.
149. K. Nooter, A.M. Westerman, M.J. Flens, G.J. Zaman, R.J. Scheper, K.E. van Wingerden, et al. (1995) Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res. 1 1301-1310.
150. K. Nooter, E.T. Bosman, H. Burger, K.E. van Wingerden, M.J. Flens, R.J. Scheper, R.G. Oostrum, A.W. Boersma, A. van der Gaasl and G. Stoter (1996) Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann. Oncol. 7 75-81.
151. K. Nooter, H. Burger and G. Stoter (1996) Multidrug resistance-associated protein (MRP) in haematological malignancies. Leuk. Lymphoma 20 381-387.
152. K. Nooter, G. Brutel de la Riviere, M.P. Look, K.E. van Wingerden, S.C. Henzen-Logmans, R.J. Scheper, M.J. Flens, J.G. Klijn, G. Stoter and J.A. Foekens (1997) The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br. J. Cancer 76 486-493.
153. M. Oka, M. Fukuda, A. Sakamoto, H. Takatani, M. Fukuda, H. Soda and S. Kohno (1997) The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res. 17 721-724.
154. Y. Oshika, M. Nakamura, T. Tokunaga, Y. Fukushima, Y. Abe, Y. Ozeki, H. Yamazaki, N. Tamaoki and Y. Ueyama (1998) Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod. Pathol. 11 1059-1063.
155. V.R. Panday, M.T. Huizing, P.H. Willemse, A. De Graeff, W.W. ten Bokkel Huinink, J.B. Vermorken and J.H. Beijnen (1997) Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin. Oncol. 24(Suppl. II), 34-38.
156. A. Patnaik, E. Warner, M. Michael, M.J. Egorin, M.J. Moore, L.L. Siu, et al. (2000) Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. J. Clin. Oncol. 18 3677-3689.
157. C.C. Paulusma, P.J. Bosma, G.J.R. Zaman, C.T.M. Bakker, M. Otter, G.L. Scheffer, R.J. Scheper, P. Borst and R.P.J. Oude Elferink (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271 1126-1128.
158. R.A. Peck, J. Hewett, M.W. Harding, Y.M. Wang, P.R. Chaturvedi, A. Bhatnagar, H. Ziessman, F. Atkins and M.J. Hawkins (2001) Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol. 19 3130-3141.
159. T. Perri, M. Fogel, S. Mor, G. Horev, I. Meller, D. Loven, et al. (2001) Effect of P-glycoprotein expression on outcome in the Ewing family of tumors. Pediatr. Hematol. Oncol. 18 325-334.
160. D. Piwnica-Worms, M.L. Chiu, M. Budding, J.F. Kronaauge, R.A. Kramer and J.M. Croop (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 53 977-984.
161. S.K. Rabindran, H. He, M. Singh, E. Brown, K.I. Collius, T. Annable and L.M. Greenberger (1998) Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. 58 5850-5858.
162. M. Ramachandra, S.V. Ambudkar, D. Chen, C.A. Hrycyna, S. Dey, M.M. Gottesman and I. Pastan (1998) Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37 5010-5019.
163. M.V. Relling (1996) Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Therap. Drug Monit. 18 350-356.
164. J.R. Riordan and V. Ling (1979) Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J. Biol. Chem. 254 12701-12705.
165. R. Robey, S. Bakke, W. Stein, B. Meadows, T. Litman, S. Patil, T. Smith, T. Fojo and S. Bates (1999) Efflux of rhodamine from CD56+cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 93 306-314.
166. R.W. Robey, W.Y. Medina-Perez, K. Nishiyama, T. Lahusen, K. Miyake, T. Litman, A.M. Senderowicz, D.D. Ross and S.J. Bates (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res. 7 145-152.
167. D.E. Rollins and C.D. Klaassen (1979) Biliary excretion of drugs in man. Clin. Pharmacokinet. 4 368-379.
168. D.D. Ross, J.F. Karp, T.T. Chen and L.A. Doyle (2000) Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96 365-368.
169. L. Smith, Y.M. Wang, P. Chaturvedi, M. Vilialona, I. Campbell, et al. (1998) Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 16 2964-2976.
170. A. Samdani, U. Vijapurkar, M.A. Grimm, C.S. Spier, T.M. Grogan, B.J. Glinsmann-Gibson and A.F. List (1996) Cytogenetics and P-glycoprotein (P-GLYCOPROTEIN) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk. Res. 20 175-180.
171. Z.E. Sauna and S.V. Ambudkar (2001) Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J. Biol. Chem. 276 11653-11661.
172. N. Savaraj, C.J. Wu, R. Xu, T. Lampidis, S. Lai, E. Donnelly, J. Solomon and L.G. Leun (1997) Multidrug-resistant gene expression in small-cell lung cancer. Am. J. Clin. Oncol. 20 398-403.
173. S. Scala, N. Akhmed, U.S. Roa, K. Paull, B. Dickstein, J.-S. Lee, G.H. Elgemeie, W.D. Stein and S.E. Bates (1997) P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol. Pharmacol. 51 1024-1033.
174. G.L. Schetter, M. Kool, M. Heijn, M. de Haas, A.C. Pijnenborg, J. Wijnholds, et al. (2000) Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res. 60 5269-5277.
175. G.L. Scheffer, A.B. Schroeijers, M.A. Izquierdo, E.A. Wiemer and R.J. Scheper (2000) Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr. Opin. Oncol. 12 550-556.
176. A.H. Schinkel, J.J. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter, et al. (1994) Disruption of mouse mdr-1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 491-502.
177. A.H. Schinkel, U. Mayer, E. Wagenaar, C.A. Mol, L. van Deemter, J.J. Smit, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94 4028-4033.
178. J. Schneider, E. Jimenez, K. Marenbach, D. Marx and H. Meden (1998) Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. Anticancer Res. 18 2967-2971.
179. J. Schneider, S. Gonzalez-Roces, M. Pollan, R. Lucas, A. Tejerina, M. Martin and A. Alba (2001) Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res. 3 183-191.
180. K.W. Scotto, J.L. Biedler and P.W. Melera (1986) Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 232 751-755.
181. A.E. Senior and S. Bhagat (1998) P-glycoprotein shows strong catalytic cooperativity between the two nucleotide sites. Biochemistry 37 831-836.
182. J.J.M. Smit, A.H. Schinkel, R.P.J. Oude Elferink, A.K. Groen, E. Wagenaar, L. van Deemter, et al. (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75 451-462.
183. E. Solary, I. Velay, B. Chauffert, J.M. Bidan, D. Caillot, M. Dumas and H. Guy (1991) Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68 1714-1719.
184. S. Song, H. Suzuki, R. Kawai, C. Tanaka, I. Akasaka and Y. Sugiyama (1998) Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab. Dispos. 26 1128-1133.
185. P. Sonneveld, J.-P. Marie, C. Huisman, A. Vekhoff, M. Schoester, A.M. Faussat, et al. (1996) Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 10 1741-1750.
186. A. Sparreboom, A.S. Planting, R.C. Jewell, M.E. van der Burg, A. van der Gaast, P. de Bruijn, et al. (1999) Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drug 10 719-728.
187. S. J.J. Starling, R.L. Shepard, J. Cao, K.L. Law, B.H. Norman, J.S. Kroin, et al. (1997) Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv. Enzyme Regul 37 335-347.
188. B. Stieger, K. Fattinger, J. Madon, G.A. Kulla-Ublick and P.J. Meier (2000) Drug-and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118 422-430.
189. S.S. Srautnieks, L.N. Bull, A.S. Knisely, S.A. Kocoshis, N. Dahl, H. Arnell, et al. (1998) A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 20 233-238.
190. S.S. Sun, J.F. Hsieh, S.C. Tsai, Y.J. Ho, J.K. Lee and C.H. Kao (2000) Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results. Cancer Lett. 153 95-100.
191. K. Taniguchi, M. Wada, K. Kohno, T. Nakamura, T. Kawabe, M. Kawakami, K. Kagotani, K. Okumura, S. Akiyama and M. Kuwano (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56 4124-4129.
192. C.W. Taylor, W.S. Dalton, K. Mosley, R.T. Dorr and S.E. Salmon (1997) Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Res. Treat. 42 7-14.
193. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan and M.C. Willingham (1987) Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 84 7735-7738.
194. B. Thurlimann, N. Kroger, J. Greiner, K. Mross, J. Schuller, E. Schernhammer, et al. (1995) Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J. Cancer Res. Clin. Oncol. 121(Suppl. 3), R3-R6.
195. U. Tidefelt, J. Liliemark, A. Gruber, E. Liliemark, B. Sundman-Engberg, G. Juliusson, et al. (2000) P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J. Clin. Oncol. 18 1837-1844.
196. S. Toh, M. Wada, T. Uchiumi, A. Inokuchi, Y. Makino, Y. Horie, Y. Adachi, S. Sakisaka and M. Kuwano (1999) Genomic structure of the canalicular multispecific organic aniontransporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 64 739-746.
197. A.W. Tolcher, K.H. Cowan, D. Solomon, F. Ognibene, B. Goldspiel, R. Chang, et al. (1996) Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J. Clin. Oncol. 14 1173-1184.
198. B.J. Trock, F. Leonessa and R. Clarke (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance [see comments]. J. Natl. Cancer Inst. 89 917-931.
199. T. Tsuruo, H. Iida, S. Tsukagoshi and Y. Sakurai (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41 1967-1972.
200. K. Ueda, D.P. Clark, C.D. Chen, I.B. Roninson, M.M. Gottesman and I. Pastan (1987) The human multidrug resistance (mdr1) gene. J. Biol. Chem. 262 505-508.
201. J. van Asperen, A.H. Schinkel, J.H. beijnen, W.J. Nooijen, P. Borst and O. van Ichingen (1996) Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J. Natl Cancer Inst. 88 994-999.
202. J. van Asperen, O. van Tellingen, F. Tijssen, A.H. Schinkel and J.H. Beijnen (1999) Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer 79 108-113.
203. D.M. van der Kolk, T.G. de Vries, M. van Tullen, I. Neider, G.J. Osseokoppek, G.L. Verhoel and L. Vellenga (2000) P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin. Cancer Res. 6 3205-3214.
204. A.G. van der Zee, H. Hollema, A.J. Suurmeijer, M. Krans, W.J. Sluiter, P.H. Willemse, J.G. Aalders and E.G. de Vries (1995) Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 13 70-78.
205. M. Muller, C.F. Higgins and W.N. Konings (2000) The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism. EMBO J. 19 2503-2514.
206. L. An Zuylen, A. Sparreboom, A. van der Gaast, M.P. van der Burg, V. van Beurden and R. Westenborghs (2000) The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin. Cancer Res. 6 1365-1371.
207. L. van Zuylen, K. Nooter, A. Sparseboom and J. Verweij (2000) Development of multidrug-resistance convertors: sense or nonsense? Invest. New Drugs 18 205-220.
208. S.D. Vecchio, A. Ciarmiello, M.I. Potena, M.V. Carriero, C. Mainolfi, G. Botti, et al. (1997) In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur. J. Nucl. Med. 24 150-159.
209. G. Visani, D. Milligan, F. Leoni, J. Chang, S. Kelsey, R. Marcus, et al. (2001) Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia 15 764-771.
210. V.J. Wacher, C.Y. Wu and L.Z. Benet (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13 129-134.
211. C.S. Wang, H. LaRue, A. Fortin, G. Gariepy and B. Tetu (1997) mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res. Treat. 45 63-74.
212. R. Wang, M. Salem, I.M. Yousef, B. Tuchweber, P. Lam, S.J. Childs, C.D. Helgason, C. Ackerley, M.J. Phillips and V. Ling (2001) Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Natl Acad. Sci. USA 98 2011-2016.
213. J. Wijnholds, C.A.A.M. Mol, L. van Deemter, M. de Haas, G.I. Scheffer, E. Baas, et al. (2000) Multidrug resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl Acad. Sci. USA 97 7476-7481.
214. J. Wijnholds, E.C.M. de Lange, G.L. Scheffer, D.-J. van den Berg, C.A.A.M. Mol, M. van der Valk, A.H. Schinkel, R.J. Scheper, D.D. Breimer and P. Borst (2000) Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105 279-285.
215. W.H. Wilson, S.E. Bates, A.T. Fojo, G. Bryant, Z. Zhan, J. Regis, et al. (1995) Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. Clin. Oncol. 13 1995-2004.
216. S.M. Witherspoon, D.L. Emerson, B.M. Kerr, T.L. Lloyd, W.S. Dalton and P.S. Wissel (1996) Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin. Cancer Res. 2 7-12.
217. S.R. Wright, A.H. Boag, G. Valdimarsson, D.R. Hipfner, B.G. Campling, S.P.C. Cole and R.G. Deeley (1998) Immuno-histochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin. Cancer Res. 4 2279-2289.
218. J.S. Wander, S.B. Bull, V. Aneliunas, P.D. Lee, A.M. Davis, C.P. Beauchamp, et al. (2000) MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J. Clin. Oncol. 18 2685-2694.
219. D. Xu, L. Arestrom, R. Virtala, P. Pisa, C. Peterson and A. Gruber (1999) High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. Br. J. Haematol. 106 627-633.
220. Y. Yamamoto, Y. Nishiyama, K. Satoh, H. Takashima, M. Ohkawa, J. Fujita, T. Kishi, S. Matsuno and M. Fanabe (1998) Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J. Nucl. Med. 39 1626-1629.
221. X. Yang, B. Uziely, S. Groshen, J. Lukas, V. Israel, C. Russell, G. Dunnington, S. Founchil, F.. Muggia and M.F. Press (1999) MDR1 gene expression in primary and advanced breast cancer. Lab. Invest. 79 271-280.
222. T. Ishida, K. Sugio, T. Inoue and K. Sugmachi (1999) Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival. Surg. Today 29 1141-1147.
223. Y. Yokoyama, S. Sato, Y. Fukushi, T. Sakamoto, M. Futagami and Y. Saito (1999) Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J. Obstet. Gynaecol. Res. 25 387-394.
224. L.C. Young, B.G. Campling, T. Voskoglou-Nomikos, S.P.C. Cole, R.G. Deeley and J.H. Gerlach (1999) Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin. Cancer Res. 5 673-680.
225. L.C. Young, B.G. Campling, S.P.C. Cole, R.G. Deeley and J.H. Gerlach (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. 7 1798-1804.
226. H. Zeng, L.J. Bain, M.G. Belinsky and G.D. Kruh (1999) Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 59 5964-5967.
227. Y. Zhou, M.M. Gottesman and I. Pastan (1999) Studies of human MDR1-MDR2 chimeras demonstrate the functional exchangeability of a major transmembrane segment of the multidrug transporter and phosphatidylcholine flippase. Mol. Cell. Biol. 19 1450-1459.